Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Nov 14, 2017)
  • 8-K (Nov 8, 2017)
  • 8-K (Nov 2, 2017)
  • 8-K (Oct 30, 2017)
  • 8-K (Oct 26, 2017)
  • 8-K (Oct 12, 2017)

 
Other

PDL BioPharma 8-K 2014

Documents found in this filing:

  1. 8-K
  2. 8-K
pdli20140415_8k.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): April 9, 2014

 

PDL BioPharma, Inc.

(Exact name of Company as specified in its charter)

 

000-19756
(Commission File Number)

 

 

Delaware

 

94-3023969

(State or Other Jurisdiction of

 

(I.R.S. Employer Identification No.)

Incorporation)

 

 

 

932 Southwood Boulevard
Incline Village, Nevada 89451

(Address of principal executive offices, with zip code)

 

(775) 832-8500
(Company’s telephone number, including area code)

 

________________

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

   

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

   

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

   

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

2014/18 Long-Term Incentive Plan

 

On April 9, 2014, the Compensation Committee of the Board of the Directors of PDL BioPharma, Inc. (the Compensation Committee) approved a long-term incentive plan to compensate, retain and incentivize its executive officers (the 2014/18 LTIP). The Compensation Committee designated the effective date of the 2014/18 LTIP as January 1, 2014.

 

Under the 2014/18 LTIP, each executive officer is eligible for awards consisting of restricted stock and cash payments (the Awards) upon the attainment of specified performance goals related to (i) the amount of income generating asset acquisitions accomplished and (ii) the Company’s cash flows from income generating assets. The Compensation Committee fashioned the 2014/18 LTIP so that all awards under the plan are at risk if certain performance criteria are not met.

 

Each executive officer’s restricted stock award was granted on April 10, 2014, and the number of shares underlying the restricted stock award was determined based on the closing price of the Company’s common stock on April 10, 2014, which was $8.22 per share (rounded to the nearest whole share).

 

Subject to the acceleration provisions set forth in the severance agreements of the executive officers (disclosed on May 26, 2011), portions of the Awards will vest in December of years two through five of the 2014/18 LTIP, provided the executive officer remains employed by the Company through such date and the specified performance criteria have been accomplished as set forth in the chart below:

 

Date

 

Performance Criteria

 

Percent of the Awards Vesting

December 2015

  

Accomplish in each of years 1 and 2 at least $200 million of income generating asset acquisitions

  

50%

December 2016

  

Maintain cash flows at 75% or greater of forecasted cash flows for income generating assets in year 3

  

16.66%

December 2017

 

Maintain cash flows at 75% or greater of forecasted cash flows for income generating assets in year 4

 

16.66%

December 2018

 

Maintain cash flows at 75% or greater of forecasted cash flows for income generating assets in year 5

 

16.66%

 

 
 

 

 

In the event that the performance criteria are not met in any of years three through five but at the conclusion of the 2014/18 LTIP the combination of the three years results in maintenance of cash flows at 75% or greater than forecasted cash flows for the three year period, then any Awards that did not vest during the three year period shall vest and pay. Dividend payments and other distributions made on the restricted stock during the vesting period of the restricted stock will accrue through the vesting period and will be paid, plus interest, to the executive officer upon vesting of the restricted stock award.

 

The target Awards for each executive officer are set forth in the chart below:

 

Name

 

Title

 

Total Target

Cash Payment

 

Total Target Value of

Restricted Stock Award

 

Number of Shares Underlying

Restricted Stock Award

John P. McLaughlin

  

President and Chief Executive Officer 

  

$2,297,190

 

$984,510

 

119,770

Christopher L. Stone

  

Vice President, General Counsel and Secretary

  

$558,700

 

$252,300

 

30,693

Peter Garcia

 

Vice President and Chief Financial Officer

 

$584,023

 

$250,295

 

30,450

Danny Hart

 

Deputy General Counsel and Assistant Secretary

 

$472,500

 

$202,500

 

24,635

David Montez

 

Controller and Chief Accounting Officer

 

$212,660

 

$91,140

 

11,088

 

 
 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

PDL BioPharma, inc.

 

  (Company)  

 

 

 

 

 

By:

/s/ John P. McLaughlin

 

 

 

John P. McLaughlin

 

 

 

President and Chief Executive Officer

 

 

 

Dated: April 15, 2014

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki